Atlas Trials

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Clinical trial NCT00144222 · COMPLETED

Trial details

NCT number
NCT00144222
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hypertension
Start date
2005-01-01
Primary completion
2005-08-01
Enrollment
218

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.